How does RNTX's Q3 2024 EPS forecast compare to past trends?

Rein Therapeutics (RNTX) has historically experienced significant declines in its Q3 EPS, with the most recent EPS of -$1.4 in 2022, followed by -$0.4 in 2023, and the latest forecasted EPS of -$0.27 for 2024. This trend suggests that RNTX is likely to continue its pattern of negative EPS in the upcoming quarter.

|code|Ticker|Name|Date|Diluted EPS YoY|Diluted EPS|market_code|
|---|---|---|---|---|---|---|
|RNTX|RNTX.O|Rein Therapeutics|2022 Q1|-2225|-1.86|186|
|RNTX|RNTX.O|Rein Therapeutics|2022 Q2|-2833.333333333333|-1.76|186|
|RNTX|RNTX.O|Rein Therapeutics|2022 Q3|-1899.9999999999995|-1.4|186|
|RNTX|RNTX.O|Rein Therapeutics|2023 Q1|43.54838709677419|-1.05|186|
|RNTX|RNTX.O|Rein Therapeutics|2023 Q2|77.8409090909091|-0.39|186|
|RNTX|RNTX.O|Rein Therapeutics|2023 Q3|71.42857142857143|-0.4|186|
|RNTX|RNTX.O|Rein Therapeutics|2024 Q1|18.095238095238102|-0.86|186|
|RNTX|RNTX.O|Rein Therapeutics|2024 Q2|-15.384615384615383|-0.45|186|
|RNTX|RNTX.O|Rein Therapeutics|2024 Q3|32.5|-0.27|186|